Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ORGANIZATION
ORGANIZATION
- JBPO Looks to Boost Japan’s Self-Sufficiency Ratio of Plasma Derivatives, Mulls Further Integration: Pres. Ueda
October 18, 2012
- Mr Kaiya of Kyokai Kenpo Optimistic About Reaching 30% Generic Drug Use Target
October 18, 2012
- Sino-Japanese Pharmaceutical Exchange Symposium to Be Postponed at Request of China: OPMA
October 15, 2012
- OPMA Temporarily Freezes JBPO’s Appointment as Its Board Member, FPMAJ’s Member of Board of Trustees
October 15, 2012
- Permanent New Drug Premium, Expanded R&D Tax Credits Needed to Encourage Innovation and Investment: FPMAJ Chairman Naito
October 12, 2012
- Price Gap between Long-Listed Products, Generics Necessary: FPMAJ Chairman Naito
October 11, 2012
- President Teshirogi of JPMA Stresses Need for Asian Countries to Cooperate in Drug Discovery
October 11, 2012
- Proposal to Unify Basic Dispensing Fees Could Be Taken Up Again: JPA Vice President Miura
October 10, 2012
- Life Science Budget in Japan Lacks Absolute Amount: JPMA President Teshirogi
October 10, 2012
- “Industry Also Needs to Consider” Distribution of Drug Expenditure: Former Administrative Vice Minister of Health Erikawa
October 5, 2012
- Enterprise Integration Has Not Yet Advanced among Drugmakers in Japan: Former JFTC Chairman Takeshima
September 27, 2012
- MHLW to Announce 14 New Examples of Approved Off-Label Drug Use Based on 1980 Notification in Near Future
September 26, 2012
- Risk for 7 Main Diseases Increases at Age 63: Anti-Aging Laboratory
September 25, 2012
- JPA Issues Notice on Prohibition of Dispensing Point Services, “Not Intended as Transitional Measure”
September 25, 2012
- Wholesale Industry FTC’s Liaison Conference on Ending Provision of Free Benefits and Labor to Hold 1st Meeting in October
September 25, 2012
- MHLW Reports Results of Analysis of “Close-Call” Incidents at Pharmacies with Generics
September 24, 2012
- Mr Hayashi of OPIR Stresses Need for Approval and Reimbursement of More Companion Diagnostics
September 21, 2012
- Dr Fukuda Lays Out 4 Options for HTA Introduction in Drug Pricing
September 20, 2012
- Anti-Japanese Demonstrations in China Have Had “Absolutely No Effect” on Takeda: President Hasegawa
September 20, 2012
- Maker FTC Bans Drink Donations at Academic Conferences
September 19, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…